Abstract:2934 Breast cancer presents as estrogen receptor alpha (ERα) positive or negative. ERα- tumors have a poor prognosis, are resistant to hormonal therapies, and frequently show overexpression, amplification, and/or hyperactivation of growth factor receptors, such as the erbB family. Using cell line models that mimic this elevated growth factor signaling by EGFR and erbB-2 in MCF-7 breast cancer cells, we have previously shown that hyperactivation of downstream p42/44 MAPK results in the reversible loss of ERα expression, and that in addition to the direct effect of MAPK on ERα, indirect activation of NFkB by MAPK also plays a role. In this study, we set out to determine if the inihibition of MAPK activity in established ERα- breast cancer cell lines could restore ERα expression and further, if this re-expressed ERα could now restore anti-estrogen response. MAPK inhibition via treatment with U0126 in 3 ERα- breast cancer cell lines, the EGFR overexpressing SUM 229s, the EGFR/c-erbB-2 dual overexperssing SUM 190s, and the RhoC overexpressing SUM 149s resulted in the sustained re-expression of ERα protein in all 3 cell lines. To ascertain that this re-expressed ERα could now restore anti-estrogen sensitivity, growth assays analyzing the effects of 4-hydroxy-tamoxifen (4HT) and the pure antiestrogen ICI 182,780 (faslodex) at 10-7 M alone, 5 μM U0126 alone, or the combination of 4HT or ICI and U0126 on cell proliferation were performed by WST-1 assay. ERα- SUM 229 and 149 cells were resistant to both 4HT and ICI. While having no growth inhibitory effects on its own, 5 μM U016 restored the growth inhibitory effects of both 4HT and ICI in ERα- SUM 229 cells, but not in SUM 149 cells. To determine if these in vitro cell line results would extrapolate to a real breast tumor situation, ERα- tumor specimens were obtained from the Tissue Procurement Core. Tumors were minced and divided evenly into a baseline sample and into tissue culture dishes containing medium alone, or supplemented with 10 μM U0126 or vehicle control DMSO. The minced tumor specimens in medium plus or minus U0126 were incubated at 37oC/5%CO2 for 20 hours. RNA was prepared from all treatment groups and analyzed for ERα mRNA level by qRT-PCR. Of the 12 tumors received to date, 6 displayed increased ERα mRNA levels after treatment with U0126. Collectively, these data are supportive of our hypothesis that there exists a population of ERα- tumors where upregulated growth factor signaling is directly involved in the generation of the ERα- phenotype by repressing ERα expression. Importanly, these data suggest that this reversible downregulation may be targeted clinically such that this repression can be reversed by inhibiting signaling through MAPK, resulting in re-expression of ERα and perhaps restoration of tamoxifen sensitivity.

Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway.

Sphingosine Kinase Transmits Estrogen Signaling in Human Breast Cancer Cells.

Sphingosine Kinase (sphk) Mediates Transactivation of the Epidermal Growth Factor Receptor (egfr) by Estrogen in Breast Cancer Cells

KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer

Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming

Abstract A46: KLF4 Overcomes Tamoxifen Resistance by Suppressing MAPK Signaling Pathway in Breast Cancer

Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism

Sphingosine kinase 2 in stromal fibroblasts creates a hospitable tumor microenvironment in breast cancer

Sphingosine-1-phosphate Receptor 1 Transmits Estrogens’ Effects in Endothelial Cells

Sphingosine Kinase (SphK) 1 and SphK2 Play Equivalent Roles in Mediating Insulin's Mitogenic Action

Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells

Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells

Lower Beclin 1 Downregulates HER2 Expression to Enhance Tamoxifen Sensitivity and Predicts a Favorable Outcome for ER Positive Breast Cancer

Novel Effects Of Sphingosylphosphorylcholine On The Apoptosis Of Breast Cancer Via Autophagy/Akt/P38 And Jnk Signaling

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2

SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway

Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

Keratinocyte Growth Factor (KGF) Regulates Estrogen Receptor-α (Er-Α) Expression and Cell Apoptosis Via Phosphatidylinositol 3-Kinase (pi3k)/akt Pathway in Human Breast Cancer Cells

The HOXB7 Protein Renders Breast Cancer Cells Resistant to Tamoxifen Through Activation of the EGFR Pathway.

Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.